

OCT 18 2007

PTO/SB/08 (2/92)  
Sheet 1 of 2

Form PTO-1449

## INFORMATION DISCLOSURE STATEMENT

Attorney's Docket No.  
39766-0222R1C1D1Application Serial No.  
09/825,584

Applicant(s)

Akita, et al.

(use several sheets if necessary)

Filing Date:  
April 4, 2001Group Art Unit:  
1643

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1		5,480,968				

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
	2		94/02602	WO				

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	3.	C. H. Heldin, Cell, vol. 80, 1995, pp. 213-223
	4.	Sliwkowski et al., The Journal of Biological Chemistry, vol. 269, 1994, pp. 14661-14665
	5.	Fiddes, Cell Growth and Differentiation, vol. 6, 1995, pp. 1567-1577
	6.	Ethier, Cancer Research, vol. 56, 1996, pp. 899-907
	7.	Lewis et al., Cancer Research, vol. 56, 1996, pp. 1457-1465
	8.	Rajkumar et al., The Breast, vol. 4, 1995, pp. 84-91
	9.	Rajkumar and Gullick, Br. J. Cancer vol. 70, 1994, pp. 459-465
	10.	Kraus et al., Proc. Natl. Acad. Sci. USA, vol. 90, 1993, pp. 2900-2904
	11.	Zhang et al., The Journal of Biological Chemistry, vol. 271, February 1996, pp. 3884-3890
	12.	Chen et al., The Journal of Biological Chemistry, vol. 271, 1996, pp. 7620-7629
	13.	Experimental Report of Dr. Treder
	14.	CV of Dr. Treder
	15.	Correspondence from 1993/1994 between Prof. Gullick and other scientists
	16.	Correspondence between U3 Pharma and the laboratory offering the antibodies used in D12
	17.	Presta, 1992, Curr. Op. Struct. Biol, vol. 2, pp. 593-596
	18.	E-mail exchange U3 Pharma/Lab Vision
	19.	Ullrich and Schlessinger, 1990, Cell, vol. 61, pp. 203-212.
	20.	Background information from U3 Pharma.
	21.	Kraus et al, PNAS, vol. 86, 1989, pp. 9193-9197.
	22.	Carraway and Cantley, Cell, vol. 78, 1994, pp.5-8.
	23.	"Molekularbiologie der Zelle" Alberts, Bruce, 1995, 3 <sup>rd</sup> edi., pp. 897-899 (German).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

<b>Form PTO-1449</b>		<b>Attorney's Docket No.</b> 39766-0222R1C1D1	<b>Application Serial No.</b> 09/825,584
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>Applicant(s)</b> Akita, et al.	
<i>(use several sheets if necessary)</i>		<b>Filing Date:</b> April 4, 2001	<b>Group Art Unit:</b> 1643
	24.	Wallasch et al., 1995, EMBO J., vol. 14, pp. 4267-4275	
	25.	Fendly et al., 1990, Cancer Res., vol. 50, pp. 1550-1558	
	26.	Alimandi et al, 1995, Oncogene, vol. 10, pp. 1813-1821	
	27.	Declaration of Dr. Nielsen	
	28.	Rajkumar and Gullick, 1994, Breast Cancer Research and Treatment, vol 29, pp. 3-9	
	29.	Levi et al., 1995, J. Neuroscience, vol. 15, pp. 1329-1340	
	30.	Gammet et al, 1995, J. Biol. Chem., vol. 270, pp. 19022-19027	

<b>EXAMINER:</b>	<b>DATE CONSIDERED:</b>
<b>EXAMINER:</b> Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	